

Form PTO-1449 (modified)

ATTY. DOCKET NO.
UROC:018USD2/GNSSerial No.
09/974,546

U.S. Department of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicants

David Ralph, Gang An, Mark O'Hara and Robert Veltri

Filing Date:
October 10, 2001Group:
UnknownU.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.
SR	A1	5,262,311	11/16/93	Pardee <i>et al.</i>	435	91.2; 6	
	A2	5,633,161	05/27/97	Shyjan	435	325	
	A3	5,639,656	06/17/97	Wright, Jr.	435	344.1	
	A4	5,665,547	09/09/97	Pardee <i>et al.</i>	435	6	
	A5	5,342,762	08/30/94	Mosher <i>et al.</i>	435	69.1	
	A6	5,455,158	10/03/95	Vogel <i>et al.</i>	435	7.21	
	A7	5,487,985	01/30/96	McClelland <i>et al.</i>	435	91.2	
	A8	5,550,214	08/27/96	Eberlain <i>et al.</i>	530	328	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
SR	B1	WO 94/10343	05-11-94	PCT	C12Q	1/68	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SR	C1	Alcaraz <i>et al.</i> , "Aneuploidy and aneusomy of chromosome 7 detected by fluorescence <i>in situ</i> hybridization are markers of poor prognosis in prostate cancer", <i>Cancer Res.</i> , 54:3998-4002, 1994.
	C2	An <i>et al.</i> , "Isolation of Genes differentially expressed in prostate cancer cells with metastatic potential by arbitrarily-primed differential analyses (ADA)", <i>Proc. Amer. Assn. Canc. Res.</i> , 36:82(491), 1995.
	C3	Bookstein <i>et al.</i> , "Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene," <i>Science</i> , 247:712-715, 1990.

25096157.1

Examiner:

Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

A: 174969(25096157_1.DOC)

RECEIVED

JAN 28 2002

TECH CENTER 1600/2900



Form PTO-1449 (modified)ATTY. DOCKET NO.
UROC:018USD2/GNSSerial No.
09/974,546

List of Patents and Publications for Applicant's

Applicants

David Ralph, Gang An, Mark O'Hara and Robert Veltri

Filing Date:
October 10, 2001Group:
Unknown**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
82	C4	Bookstein <i>et al.</i> , "Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma," <i>Proc. Natl. Acad. Sci. USA</i> , 87:7762-7766, 1990.
	C5	Bova <i>et al.</i> , "Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer," <i>Cancer Res.</i> , 53:3869-3873, 1993.
	C6	Carter <i>et al.</i> , "Allelic loss of chromosomes 16q and 10q in human prostate cancer," <i>Proc. Natl. Acad. Sci. USA</i> , 87:8751-8755, 1990.
	C7	Chen <i>et al.</i> , "Androgen-independent human prostate cancer progression: the isolation of novel stage-specific sequences using differential mRNA display," <i>Proc. Natl. Urol. Assn.</i> , 153:267A, 1995.
	C8	Donohue <i>et al.</i> , "A delayed-early gene activated by fibroblast growth factor-1 encodes a protein related to aldose reductase", <i>J. Biol. Chem.</i> , 269(11):8604-8609, 1994.
	C9	Dumont <i>et al.</i> , "Relationship between multiple biologic effects of rapamycin and the inhibition of pp70S6 protein kinase activity," <i>J. Immunology</i> , 992-1003, 1994.
	C10	Isaacs <i>et al.</i> , "Molecular biology of prostate cancer," <i>Seminars in Oncology</i> , 21(5):514-521, 1994.
	C11	Isaacs <i>et al.</i> , "Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 Alleles," <i>Cancer Res.</i> , 51:4716-4720, 1991.
	C12	Liang, Peng, Pardee, "Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction", <i>Science</i> , 257:967-971, 1992.
	C13	Liang <i>et al.</i> , "Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells", <i>Cancer Res.</i> , 52:6966-6968, 1992.
	C14	Macoska <i>et al.</i> , "Fluorescence in Situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer", <i>Cancer Research</i> , 54:3824-3830, 1994.
	C15	Mok <i>et al.</i> , "Molecular cloning of differentially expressed genes in human epithelial ovarian cancer", <i>Gynecological Oncology</i> , 52:247-252, 1994.
	C16	Morton <i>et al.</i> , "Multivariate analysis of the relationship between survival and the microstage of primary melanoma by clark level and breslow thickness," <i>Cancer</i> , 71(11):3737-3743, 1993.

25096157.1

Examiner:

Date Considered:

11/1/04

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

A: 174969(25096157_1.DOC)

RECEIVED

JAN 28 2002

TECH CENTER 1600/2900



Form PTO-1449 (modified)

ATTY. DOCKET NO.

Serial No.

UROC:018USD2/GNS

09/974,546

List of Patents and Publications for Applicant's

Applicants

David Ralph, Gang An, Mark O'Hara and Robert Veltri

Filing Date:

Group:

October 10, 2001

Unknown

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SR	C17	Morton <i>et al.</i> , "Reduction of E-cadherin levels and deletion of the α -catenin gene in human prostate cancer cells," <i>Cancer Research</i> , 53:3585-3590, 1993.
	C18	Qiao <i>et al.</i> , "Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells", <i>Biochemical and Biophysical Research Communications</i> , 201(2):581-588, 1994.
	C19	Riber, Manuel, Rieber, "Cyclin-dependent kinase 2 and cyclin A interaction with E2F are targets for tyrosine induction of B16 melanoma terminal differentiation", <i>Cell Growth and Differentiation</i> , 5:1339-1346, 1994.
	C20	Sager <i>et al.</i> , "Identification by differential display of alpha-6 integrin as a candidate tumor suppressor gene," <i>Methodology Communications</i> , 7:964-970, July, 1993.
	C21	Scott <i>et al.</i> , "A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells," <i>Molecular and Cellular Biology</i> , 13(4):2247-2257, 1993.
	C22	Slamon <i>et al.</i> , "Expression of cellular oncogenes in human malignancies," <i>Science</i> , 224:256-262, 1984.
	C23	Takahashi <i>et al.</i> , "Potential markers of prostate cancer aggressiveness detected by fluorescence <i>in Situ</i> hybridization in needle biopsies," <i>Cancer Research</i> , 54:3574-3579, 1994.
	C24	Umbas <i>et al.</i> , "Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer," <i>Cancer Research</i> , 52:5104-5109, 1992.
	C25	Visakorpi <i>et al.</i> , "Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence <i>In Situ</i> hybridization," <i>J. Pathology</i> , 145(3):624-630, 1994.
	C26	Watson and Fleming, "Isolation of differentially expressed sequence tags from human breast cancer," <i>Cancer Research</i> , 54:4598-4602, 1994.
	C27	Webb and Lin, "Urinary fibronectin-potential as a biomarker in prostatic cancer," <i>Investigative Urology</i> , 17(5):401-404, 1980.
	C28	Welsh <i>et al.</i> , "Arbitrarily primed PCR fingerprinting of RNA," <i>Nucleic Acids Research</i> , 20(19):4965-4970, 1992.

25096157.1

Examiner:

Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Information Disclosure Statement — PTO-1449 (Modified)

A: 174969(25096157_1.DOC)

RECEIVED

JAN 2 8 2002

TECH CENTER 1600/2900



Form PTO-1449 (modified)ATTY. DOCKET NO.
UROC:018USD2/GNSSerial No.
09/974,546


List of Patents and Publications for Applicant's

Applicants

David Ralph, Gang An, Mark O'Hara and Robert Veltri

Filing Date:
October 10, 2001Group:
Unknown**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

RECEIVED
 JAN 28 2002
 TECH CENTER 160012900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SR	C29	Wong <i>et al.</i> , "Identification of differentially expressed RNA in human ovarian carcinoma cells by arbitrarily primed PCR fingerprinting of total RNAs," <i>Intl. J. Onc.</i> , 3:13-17, 1993.
	C30	An <i>et al.</i> , "Identification of novel gene markers in prostate disease by RNA fingerprinting," <i>Proc. American Assoc. Cancer Res. Annual Mtg</i> , Abstract No. 1692 37(0):248, 1996.
	C31	An <i>et al.</i> , "Sensitive, nonradioactive differential display method using chemiluminescent detection," <i>Biotechniques</i> , 20(3):342, 344, 346, 1996.
	C32	Blok <i>et al.</i> , "Isolation of cDNAs that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR™," <i>Prostate</i> , 26(4):213-224, 1995.
	C33	Hamdy <i>et al.</i> , "Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer," <i>Brit. J. Urology</i> , 69(4):392-396, 1992.
	C34	Robson <i>et al.</i> , "Identification of prostatic androgen regulated genes using the differential display technique," <i>Proc. American Assoc. Cancer Research Annual Meeting</i> , Abstract No. 1589. 36:266, 1995.
	C35	EMBL. Sequence Data Library, Heidelberg, BRD, XP002019347, Accession no. W67972
	C36	PCT Search Report mailed March 7, 1997.
	C37	Adam and Wright Jr., "Identification of biomarkers in benign: prostate hyperplasia and prostate carcinoma by differential display," <i>Proceedings</i> , 86th Annual Meeting American Association for Cancer Research, March 1995.
	C38	Badalament <i>et al.</i> , "An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level," <i>J. Urol.</i> , 156:1375-1380, 1996.
	C39	Bussemakers <i>et al.</i> , "Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis," <i>Cancer Res.</i> , 51:606-611, 1991.
	C40	Deguchi <i>et al.</i> , "Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction," <i>Cancer Research</i> , 53:5350-5354, 1993.

25096157.1

Examiner:

Date Considered:

11/1/04

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

Form PTO-1449 (modified)

ATTY. DOCKET NO.

Serial No.

UROC:018USD2/GNS

09/974,546

List of Patents and Publications for Applicant's

Applicants

INFORMATION DISCLOSURE STATEMENT

David Ralph, Gang An, Mark O'Hara and Robert Veltri

(Use several sheets if necessary)

Filing Date:

Group:

October 10, 2001

Unknown

Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SR	C41	Garcia-Arenas <i>et al.</i> , "The expression of prostatic acid phosphatase in transcriptionally regulated in human prostate carcinoma cells," <i>Mol. Cell. Endocrin.</i> , 111:29-37, 1995.
	C42	Kawasaki and Wang, "Detection of gene expression," <i>In: PCR Technology</i> , Henry A. Erlich (ed.), Stockton Press, 1989.
	C43	O'Dowd <i>et al.</i> , "Update on the appropriate staging evaluation for newly diagnosed prostate cancer," <i>J. Urol.</i> , 158:687-698, 1997.
	C44	Orozco <i>et al.</i> , "Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States," <i>Urology</i> , 51(2):186-195, 1998.
	C45	Prashar <i>et al.</i> , "Analysis of differential gene expression by display of 3' end restriction fragments of cDNAs," <i>Proc. Natl. Acad. Sci. USA</i> , 93:569-663, 1996.
	C46	Veltri <i>et al.</i> , "Ability to predict biochemical progression using gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei," <i>Urology</i> , 48(5):685-691, 1996.
	C47	Wingo <i>et al.</i> , "An adjustment to the 1997 estimate for new prostate cancer cases," <i>CA-A Cancer Journal for Clinicians</i> , 47(4):239-242, 1997.
	C48	An <i>et al.</i> , "Differential expression of full-length and a truncated Her-2/ <i>neu</i> oncogene receptor in prostate cancer assessed using relative quantitative RT-PCR," <i>Molecular Urology</i> , 2(4):305-310, 1998.
	C49	Veltri <i>et al.</i> , "Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer," <i>Urology</i> , 53(1):139-147, 1999.
	C50	Veltri <i>et al.</i> , "The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis," <i>Seminars in Urologic Oncology</i> , 16(3):106-117, 1998.
	C51	Chen <i>et al.</i> , "Androgen-independent human prostate cancer progression: the isolation of novel stage-specific sequences using differential mRNA display," <i>J. Urol.</i> , 153(Supp. 4):267, Abstract 154, April 1995.
	C52	Adam <i>et al.</i> , "Identification of biomarkers in benign prostate hyperplasia and prostate carcinoma by differential display," <i>Proc. Amer. Assoc. Cancer Res.</i> , 36:25, Abstract 150, March 1995.

25096157.1

Examiner:


Date Considered:

11/1/04

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

A: 174969(25096157_1.DOC)



RECEIVED
JAN 28 2002
TECH CENTER 1600/2600